Mechanism-Based Inhibition of Human Cytochrome P450 2B6 by Ticlopidine, Clopidogrel, and the Thiolactone Metabolite of Prasugrel

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Drug Metabolism And Disposition

• Publication date

  2009-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.108.022988PMID 19047469
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine.

  2008cited by this paper
• Prasugrel, a New Thienopyridine Antiplatelet Drug, Weakly Inhibits Cytochrome P450 2B6 in Humans

  2008cited by this paper
• The Biotransformation of Prasugrel, a New Thienopyridine Prodrug, by the Human Carboxylesterases 1 and 2

  2008cited by this paper
• Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.

  2007cited by this paper
• A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.

  2007cited by this paper
• Prasugrel versus clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• The Disposition of Prasugrel, a Novel Thienopyridine, in Humans

  2007cited by this paper
• A Comparison of 2-Phenyl-2-(1-piperidinyl)propane (PPP), 1,1′,1″-Phosphinothioylidynetrisaziridine (ThioTEPA), Clopidogrel, and Ticlopidine as Selective Inactivators of Human Cytochrome P450 2B6

  2007cited by this paper
• INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450

  2006cited by this paper
• Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.

  2006cited by this paper
• Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.

  2005cited by this paper
• Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.

  2005cited by this paper
• Effect of Clopidogrel and Ticlopidine on Cytochrome P450 2B6 Activity as Measured by Bupropion Hydroxylation

  2005cited by this paper
• Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.

  2004influential reference
• Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes p450, and monoamine oxidases.

  2004cited by this paper
• Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine

  2004influential reference
• Identification of the active metabolite of ticlopidine from rat in vitro metabolites

  2004cited by this paper
• Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.

  2003cited by this paper
• The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments

  2003cited by this paper
• Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression

  2003cited by this paper
• Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19.

  2001cited by this paper
• An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.

  2000cited by this paper
• Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.

  2000cited by this paper
• In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.

  2000influential reference
• The role of CYP2B6 in human xenobiotic metabolism.

  1999cited by this paper
• Monospecific antipeptide antibody to cytochrome P-450 2B6.

  1999cited by this paper
• The Antiplatelet Effects of Ticlopidine and Clopidogrel

  1998cited by this paper
• Clinical Pharmacokinetics of Ticlopidine

  1994cited by this paper
• The potential use of mechanism-based enzyme inactivators in medicine.

  1988cited by this paper

• New insights into metabolism of desogestrel in humans using liver microsomes and an HPLC/UV method

  2026cites this paper
• Comprehensive Review of CYP2B6 Transcriptional Modulators, Variants, and Their Role in Drug Interactions

  2025cites this paper
• The rational use of PBPK to assess the changing DDI liability in pediatrics: Model qualification and the move towards best practice.

  2025cites this paper
• A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment

  2024cites this paper
• Mechanism-based inactivation of cytochromes P450: implications in drug interactions and pharmacotherapy

  2024cites this paper
• The effects of CYP2B6 inactivators on the metabolism of ciprofol

  2024cites this paper
• An in vitro evaluation on metabolism of mitragynine to 9-O-demethylmitragynine.

  2024cites this paper
• Decreased plasma exposure of clopidogrel active metabolite in rats after long‐term treatment with clopidogrel

  2023cites this paper
• Planta Medica In vitro assessment of the effects of silybin on CYP 2 B 6-mediated metabolism

  2023cites this paper
• Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions

  2022cites this paper
• In vitro Assessment of the Effects of Silybin on CYP2B6-mediated Metabolism

  2022cites this paper
• Inhibition of cytochrome P450 enzymes and uridine 5′-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions

  2022cites this paper
• Discovery and Activity Evaluation of the Inhibitory Effect of Four Kinds Traditional Chinese Medicine Extracts on the CYP3A4 Enzyme.

  2022cites this paper
• Evaluation of Zuo-Gui Yin Decoction Effects on Six CYP450 Enzymes in Rats Using a Cocktail Method by UPLC-MS/MS

  2022cites this paper
• Evaluation of commonly used cardiovascular drugs in inhibiting vonoprazan metabolism in vitro and in vivo

  2022cites this paper
• How Oxidative Systems Metabolise Substrates

  2020cites this paper
• Induction of Cytochrome P450 Involved in the Accelerated Blood Clearance Phenomenon Induced by PEGylated Liposomes In Vivo

  2019cites this paper
• Inhibitory Effect of Vonoprazan on the Metabolism of [14C]Prasugrel in Human Liver Microsomes

  2019cites this paper
• Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson’s Disease: From Bench to Bedside

  2019cites this paper
• Semimechanistic Population Pharmacokinetic Model to Predict the Drug–Drug Interaction Between S‐ketamine and Ticlopidine in Healthy Human Volunteers

  2018cites this paper
• Hepatic Drug Metabolism in Pediatric Patients

  2017cites this paper
• Computational Approach to Structural Alerts: Furans, Phenols, Nitroaromatics, and Thiophenes.

  2017cites this paper
• Clarification of the Mechanism of Clopidogrel-Mediated Drug–Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information

  2016cites this paper
• Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4′-OH-bupropion in vitro

  2016cites this paper
• Characterizing bupropion metabolism, pharmacokinetics and drug-drug interaction liability

  2016influential citation
• Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction.

  2015cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel

  2015influential citation
• Inhibition of in vitro metabolism of testosterone in human, dog and horse liver microsomes to investigate species differences.

  2015cites this paper
• Multiple Cytochrome P450 Isoforms Are Involved in the Generation of a Pharmacologically Active Thiol Metabolite, whereas Paraoxonase 1 and Carboxylesterase 1 Catalyze the Formation of a Thiol Metabolite Isomer from Ticlopidine

  2014cites this paper
• In vitro metabolism of a novel antithrombotic compound, S002-333, and its enantiomers: quantitative cytochrome P450 phenotyping, metabolic profiling and enzyme kinetic studies

  2014cites this paper
• Multiple Cytochrome P450 Isoforms Are Involved in the Generation of a Pharmacologically Active Thiol Metabolite, whereas Paraoxonase 1 and Carboxylesterase 1 Catalyze the Formation of a Thiol Metabolite Isomer from Ticlopidine s

  2013cites this paper
• Sucralose, A Synthetic Organochlorine Sweetener: Overview of Biological Issues

  2013cites this paper
• Pharmacogenomics and Personalized Medicine of the Antiplatelet Drugs

  2013cites this paper
• Different Effects of Clopidogrel and Clarithromycin on the Enantioselective Pharmacokinetics of Sibutramine and its Active Metabolites in Healthy Subjects

  2013cites this paper
• Mechanisms and quantitative prediction of Efavirenz metabolism, pharmacogenetics and drug interactions

  2013cites this paper
• Thiolactone sulfoxides as new reactive metabolites acting as bis-electrophiles: implication in clopidogrel and prasugrel bioactivation.

  2013cites this paper
• Mechanism-based inhibition of CYP450: an indicator of drug-induced hepatotoxicity.

  2013cites this paper
• Comparative xenobiotic metabolism capacities and pesticide sensitivity in adults of Solea solea and Solea senegalensis.

  2013cites this paper
• Bioactivation I: Bioactivation by Cytochrome P450s

  2012cites this paper
• Metabolic activation of prasugrel: nature of the two competitive pathways resulting in the opening of its thiophene ring.

  2012cites this paper
• Pharmacokinetic basis of the antiplatelet action of prasugrel

  2012cites this paper
• Plasticity of CYP2B enzymes: structural and solution biophysical methods.

  2012cites this paper
• Progress Curve Mechanistic Modeling Approach for Assessing Time-Dependent Inhibition of CYP3A4

  2012cites this paper
• Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.

  2012cites this paper
• Drug interaction study between bupropion and ticlopidine in male CF-1 mice.

  2011cites this paper
• In Vitro Evaluation of Potential Drug-Drug Interactions with Ticagrelor: Cytochrome P450 Reaction Phenotyping, Inhibition, Induction, and Differential Kinetics

  2011cites this paper
• Combination of glutathione trapping and time-dependent inhibition assays as a predictive method drugs generating highly reactive metabolites

  2011cites this paper
• Ticlopidine-induced hepatotoxicity in a GSH-depleted rat model

  2011cites this paper
• Combination of GSH Trapping and Time-Dependent Inhibition Assays as a Predictive Method of Drugs Generating Highly Reactive Metabolites

  2011cites this paper
• Comparison of In Vitro Metabolism of Ticlopidine by Human Cytochrome P450 2B6 and Rabbit Cytochrome P450 2B4

  2011cites this paper
• Microsoft Word-74715577-file00

  2011cites this paper
• Effects of Clopidogrel on the Pharmacokinetics of Sibutramine and Its Active Metabolites

  2011cites this paper
• Mechanism-Based Inactivation of Human Cytochrome P450 2B6 by Clopidogrel: Involvement of Both Covalent Modification of Cysteinyl Residue 475 and Loss of Heme

  2011influential citation
• Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond.

  2011cites this paper
• ADME Strategies in Lead Optimization

  2010cites this paper
• Prasugrel

  2010cites this paper
• Structures of cytochrome P450 2B4 complexed with the antiplatelet drugs ticlopidine and clopidogrel .

  2010cites this paper
• Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability.

  2010cites this paper
• In Vitro Evaluation of Potential Drug-Drug Interactions with Ticagrelor: Cytochrome P450 Reaction Phenotyping, Inhibition, Induction and Differential Kinetics

  2010influential citation
• Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite

  2010cites this paper
• Short Communication Biotransformation of Prasugrel, a Novel Thienopyridine Antiplatelet Agent, to the Pharmacologically Active Metabolite

  2010cites this paper
• Chemical and biochemical aspects of drug-induced liver injury

  2010influential citation
• Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans

  2010cites this paper
• Biotransformation of Prasugrel, a Novel Thienopyridine Antiplatelet Agent, to the Pharmacologically Active Metabolite

  2010cites this paper
• Crystal Structure of a Cytochrome P450 2B6 Genetic Variant in Complex with the Inhibitor 4-(4-Chlorophenyl)imidazole at 2.0-Å Resolution

  2010cites this paper
• Prasugrel in Humans Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine , Clopidogrel , and

  2009cites this paper
• Thienopyridine therapy and risk for cardiovascular events in secondary prevention

  2009cites this paper
• Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel

  2009cites this paper